



Universiteit
Leiden
The Netherlands

Essentiality of conserved amino acid residues in β -lactamase

Chikunova, A.

Citation

Chikunova, A. (2022, May 31). *Essentiality of conserved amino acid residues in β -lactamase*. Retrieved from <https://hdl.handle.net/1887/3304732>

Version: Publisher's Version

License: [Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the University of Leiden](#)

Downloaded from: <https://hdl.handle.net/1887/3304732>

Note: To cite this publication please use the final published version (if applicable).

References

1. Simpson, G. G. *Tempo and mode in evolution*. (New York : Columbia University Press, 1944).
2. Eldredge, N. Punctuated equilibria: an alternative to phyletic gradualism. 193–224 (1989). doi:10.1515/9781400860296.193
3. Darwin, C. R. *On the origin of species by means of natural selection, or the preservation of favoured races in the struggle for life. 5th edition*. (London: John Murray, 1869).
4. Smith, J. M. Natural selection and the concept of a protein space. *Nature* **225**, 563–564 (1970).
5. Kimura, M. & Ota, T. On some principles governing molecular evolution. *Proc. Natl. Acad. Sci. U. S. A.* **71**, 2848–2852 (1974).
6. Kimura, M. Molecular evolutionary clock and the neutral theory. *J. Mol. Evol.* **26**, 24–33 (1987).
7. Kimura, M. Preponderance of synonymous changes as evidence for the neutral theory of molecular evolution. *Nature* **267**, 275–276 (1977).
8. Bloom, J. D., Wilke, C. O., Arnold, F. H. & Adami, C. Stability and the evolvability of function in a model protein. *Biophys. J.* **86**, 2758–2764 (2004).
9. Gutin, A. M., Abkevich, V. I. & Shakhnovich, E. I. Evolution-like selection of fast-folding model proteins. *Proc. Natl. Acad. Sci. U. S. A.* **92**, 1282–1286 (1995).
10. Mélin, R., Li, H., Wingreen, N. S. & Tang, C. Designability, thermodynamic stability, and dynamics in protein folding: A lattice model study. *J. Chem. Phys.* **110**, 1252–1262 (1999).
11. Zeldovich, K. B., Chen, P. & Shakhnovich, E. I. Protein stability imposes limits on organism complexity and speed of molecular evolution. *Proc. Natl. Acad. Sci. U. S. A.* **104**, 16152–16157 (2007).
12. Govindarajan, S. & Goldstein, R. A. Evolution of model proteins on a foldability landscape. *Proteins* **29**, 461–466 (1997).
13. Bershtein, S., Goldin, K. & Tawfik, D. S. Intense neutral drifts yield robust and evolvable consensus proteins. *J. Mol. Biol.* **379**, 1029–1044 (2008).
14. Rennell, D., Bouvier, S. E., Hardy, L. W. & Poteete, A. R. Systematic mutation of bacteriophage T4 lysozyme. *J. Mol. Biol.* **222**, 67–88 (1991).
15. Stiffler, M. A., Hekstra, D. R. & Ranganathan, R. Evolvability as a function of purifying selection in TEM-1 β -lactamase. *Cell* **160**, 882–892 (2015).
16. Meini, M.-R., Llarrull, L. I. & Vila, A. J. Evolution of metallo- β -lactamases: trends revealed by natural diversity and in vitro evolution. *Antibiot. (Basel, Switzerland)* **3**, 285–316 (2014).
17. Dellus-Gur, E., Toth-Petroczy, A., Elias, M. & Tawfik, D. S. What makes a protein fold amenable to functional innovation? fold polarity and stability trade-offs. *J. Mol. Biol.* **425**, 2609–2621 (2013).
18. Draghi, J. A., Parsons, T. L., Wagner, G. P. & Plotkin, J. B. Mutational robustness can facilitate adaptation. *Nature* **463**, 353–355 (2010).
19. McBride, R. C., Ogbunugafor, C. B. & Turner, P. E. Robustness promotes evolvability of thermotolerance in an RNA virus. *BMC Evol. Biol.* **8**, 231 (2008).
20. Lynch, M. The frailty of adaptive hypotheses for the origins of organismal complexity. *Proc. Natl. Acad. Sci. U. S. A.* **104 Suppl**, 8597–8604 (2007).
21. Sniegowski, P. D. & Murphy, H. A. Evolvability. *Curr. Biol.* **16**, R831–4 (2006).
22. Draghi, J. & Wagner, G. P. Evolution of evolvability in a developmental model. *Evolution* **62**, 301–315 (2008).
23. Pigliucci, M. Is evolvability evolvable? *Nat. Rev. Genet.* **9**, 75–82 (2008).
24. Zheng, J., Guo, N. & Wagner, A. Selection enhances protein evolvability by increasing mutational robustness and foldability. *Science* **370**, eabb5962 (2020).
25. Tokuriki, N. & Tawfik, D. S. Stability effects of mutations and protein evolvability. *Curr. Opin. Struct. Biol.* **19**, 596–604 (2009).
26. Meiering, E. M., Serrano, L. & Fersht, A. R. Effect of active site residues in barnase on activity and stability. *J. Mol. Biol.* **225**, 585–589 (1992).
27. Beadle, B. M. & Shoichet, B. K. Structural bases of stability-function tradeoffs in enzymes. *J. Mol. Biol.* **321**, 285–296 (2002).
28. Wang, X., Minasov, G. & Shoichet, B. K. The structural bases of antibiotic resistance in the clinically derived mutant β -lactamases TEM-30, TEM-32, and TEM-34. *J. Biol. Chem.* **277**, 32149–32156 (2002).
29. Schreiber, G., Buckle, A. M. & Fersht, A. R. Stability and function: two constraints in the evolution of barstar and other proteins. *Structure* **2**, 945–951 (1994).
30. Arnold, F. H. How proteins adapt: Lessons from directed evolution. *Cold Spring Harb. Symp. Quant. Biol.* **74**, 41–46 (2009).
31. Risso, V. A. *et al.* Mutational studies on resurrected ancestral proteins reveal conservation of site-specific amino acid preferences throughout evolutionary history. *Mol. Biol. Evol.* **32**, 440–455 (2015).
32. Tokuriki, N., Stricher, F., Serrano, L. & Tawfik, D. S. How protein stability and new functions trade off. *PLoS Comput. Biol.* **4**, 35–37 (2008).
33. Bloom, J. D., Labthavikul, S. T., Otey, C. R. & Arnold, F. H. Protein stability promotes evolvability. *Proc. Natl. Acad. Sci. U. S. A.* **103**, 5869–5874 (2006).
34. Valdar, W. S. J. Scoring residue conservation. *Proteins Struct. Funct. Genet.* **48**, 227–241 (2002).
35. Lichtarge, O., Bourne, H. R. & Cohen, F. E. An evolutionary trace method defines binding surfaces common to protein families. *J. Mol. Biol.* **257**, 342–358 (1996).
36. Landgraf, R., Xenarios, I. & Eisenberg, D. Three-dimensional cluster analysis identifies interfaces and functional residue clusters in proteins. *J. Mol. Biol.* **307**, 1487–1502 (2001).
37. Del Sol Mesa, A., Pazos, F. & Valencia, A. Automatic methods for predicting functionally important residues. *J. Mol. Biol.* **326**, 1289–1302 (2003).
38. Jack, B. R., Meyer, A. G., Echave, J. & Wilke, C. O. Functional sites induce long-range evolutionary constraints in enzymes. *PLoS Biol.* **14**, 1–23 (2016).
39. Shakhnovich, E., Abkevich, V. & Ptitsyn, O. Conserved residues and the mechanism of protein folding. *Nature* **379**, 96–98 (1996).
40. Kragelund, B. B. *et al.* Conserved residues and their role in the structure, function, and stability of acyl-coenzyme A binding protein. *Biochemistry* **38**, 2386–2394 (1999).
41. Ptitsyn, O. B. & Ting, K. L. H. Non-functional conserved residues in globins and their possible role as a folding nucleus. *J. Mol. Biol.* **291**, 671–682 (1999).

42. Mirny, L. A. & Shakhnovich, E. I. Universally conserved positions in protein folds: Reading evolutionary signals about stability, folding kinetics and function. *J. Mol. Biol.* **291**, 177–196 (1999).
43. Khor, B. Y., Tye, G. J., Lim, T. S. & Choong, Y. S. General overview on structure prediction of twilight-zone proteins. *Theor. Biol. Med. Model.* **12**, 15 (2015).
44. Schueler-Furman, O. & Baker, D. Conserved residue clustering and protein structure prediction. *Proteins* **52**, 225–235 (2003).
45. Guharoy, M. & Chakrabarti, P. Conserved residue clusters at protein-protein interfaces and their use in binding site identification. *BMC Bioinformatics* **11**, 286 (2010).
46. Nerlich, A. G., Haas, C. J., Zink, A., Szeimies, U. & Hagedorn, H. G. Molecular evidence for tuberculosis in an ancient Egyptian mummy [10]. *Lancet* **350**, 1404 (1997).
47. Crubézy, E. *et al.* Identification of Mycobacterium DNA in an Egyptian Pott's disease of 5,400 years old. *C. R. Acad. Sci. III.* **321**, 941–951 (1998).
48. Donoghue, H. D. *et al.* Tuberculosis in Dr Granville's mummy: a molecular re-examination of the earliest known Egyptian mummy to be scientifically examined and given a medical diagnosis. *Proceedings. Biol. Sci.* **277**, 51–56 (2010).
49. Hershkovitz, I. *et al.* Detection and molecular characterization of 9,000-year-old Mycobacterium tuberculosis from a Neolithic settlement in the Eastern Mediterranean. *PLoS One* **3**, e3426 (2008).
50. Zink, A. R., Grabner, W., Reischl, U., Wolf, H. & Nerlich, A. G. Molecular study on human tuberculosis in three geographically distinct and time delineated populations from ancient Egypt. *Epidemiol. Infect.* **130**, 239–249 (2003).
51. O'Neill, M. B. *et al.* Lineage specific histories of Mycobacterium tuberculosis dispersal in Africa and Eurasia. *Mol. Ecol.* **28**, 3241–3256 (2019).
52. *Global tuberculosis report 2021. Geneva: World Health Organization.* (Licence: CC BY-NC-SA 3.0 IGO, 2021).
53. Major 1884-, R. H. *Classic descriptions of disease: with biographical sketches of the authors.* (Springfield, Ill. : Charles C. Thomas, 1945).
54. Daniel, V. S. & Daniel, T. M. Old Testament Biblical References to Tuberculosis. *Clin. Infect. Dis.* **29**, 1557–1558 (2002).
55. Bronte, E. *Wuthering Heights.* (Andrews UK, 2011).
56. Brites, D. & Gagneux, S. Co-evolution of Mycobacterium tuberculosis and Homo sapiens. *Immunol. Rev.* **264**, 6–24 (2015).
57. Dossey, L. The royal touch: a look at healing in times past. *Explore* **9** **3**, 121–127 (2013).
58. Riva, M. A. From milk to rifampicin and back again: History of failures and successes in the treatment for tuberculosis. *J. Antibiot. (Tokyo).* **67**, 661–665 (2014).
59. Daniel, T. M. Leon Charles Albert Calmette and BCG vaccine. *Int. J. Tuberc. Lung Dis. Off. J. Int. Union against Tuberc. Lung Dis.* **9**, 944–945 (2005).
60. Schatz, A., Bugle, E. & Waksman, S. A. Streptomycin, a substance exhibiting antibiotic activity against Gram-positive and Gram-negative bacteria. *Proc. Soc. Exp. Biol. Med.* **55**, 66–69 (1944).
61. Lehmann, J. E. Twenty years afterward historical notes on the discovery of the antituberculous effect of paraaminosalicylic acid (PAS) and the first clinical trials. *Am. Rev. Respir. Dis.* **90**, 953–956 (1964).
62. Millard, J., Ugarte-Gil, C. & Moore, D. A. J. Multidrug resistant tuberculosis. *BMJ* **350**, h882 (2015).
63. Centers for Disease Control and Prevention (CDC). Emergence of Mycobacterium tuberculosis with extensive resistance to second-line drugs--worldwide, 2000-2004. *MMWR. Morb. Mortal. Wkly. Rep.* **55**, 301–5 (2006).
64. World Health Organisation. WHO | Drug-resistant TB: Totally drug-resistant TB FAQ. *WHO* (2018).
65. Rowland, K. Totally drug-resistant TB emerges in India. *Nature* (2012). doi:10.1038/nature.2012.9797
66. Velayati, A. A. *et al.* Emergence of new forms of totally drug-resistant tuberculosis bacilli: super extensively drug-resistant tuberculosis or totally drug-resistant strains in Iran. *Chest* **136**, 420–425 (2009).
67. Udwardia, Z. F., Amale, R. A., Ajbani, K. K. & Rodrigues, C. Totally Drug-Resistant Tuberculosis in India. *Clin. Infect. Dis.* **54**, 579–581 (2012).
68. Plackett, B. No money for new drugs. *Nat. Outlook* **586**, S50–S52 (2020).
69. Tan, S. Y. & Tatsumura, Y. Alexander Fleming (1881-1955): Discoverer of penicillin. *Singapore Med. J.* **56**, 366–367 (2015).
70. Fernandes, R., Amador, P. & Prudêncio, C. β -Lactams: chemical structure, mode of action and mechanisms of resistance. *Rev. Med. Microbiol.* **24**, (2013).
71. Voladri, R. K. *et al.* Recombinant expression and characterization of the major beta-lactamase of *Mycobacterium tuberculosis*. *Antimicrob. Agents Chemother.* **42**, 1375–1381 (1998).
72. Fisher, J. F., Meroueh, S. O. & Mobashery, S. Bacterial resistance to beta-lactam antibiotics: compelling opportunism, compelling opportunity. *Chem. Rev.* **105**, 395–424 (2005).
73. Chambers, H. F. *et al.* Can penicillins and other β -lactam antibiotics be used to treat tuberculosis? *Antimicrob. Agents Chemother.* **39**, 2620–2624 (1995).
74. Forsman, L. D. *et al.* Meropenem-clavulanic acid has high in vitro activity against multidrug-resistant Mycobacterium tuberculosis. *Antimicrob. Agents Chemother.* **59**, 3630–3632 (2015).
75. Sharma, A. K. & Vats, P. Evaluation of biochemical and molecular polymorphism in extended spectrum β -lactamases of Mycobacterium tuberculosis clinical isolates. *Indian J. Tuberc.* **66**, 92–98 (2019).
76. Li, F. *et al.* In Vitro Activity of β -Lactams in Combination with β -Lactamase Inhibitors against Mycobacterium tuberculosis Clinical Isolates. *Biomed Res. Int.* **2018**, 1–8 (2018).
77. Dinçer, I., Ergin, A. & Kocagöz, T. The vitro efficacy of β -lactam and β -lactamase inhibitors against multidrug resistant clinical strains of Mycobacterium tuberculosis. *Int. J. Antimicrob. Agents* **23**, 408–411 (2004).
78. Davies Forsman, L. *et al.* Meropenem-clavulanate has high in vitro activity against multidrug-resistant Mycobacterium tuberculosis. *Int. J. mycobacteriology* **4**, 80–81 (2015).
79. Drawz, S. M. & Bonomo, R. A. Three decades of β -lactamase inhibitors. *Clin. Microbiol. Rev.* **23**, 160–201 (2010).
80. Kurz, S. G. *et al.* Can inhibitor-resistant substitutions in the Mycobacterium tuberculosis β -lactamase BlaC lead to clavulanate resistance?: a biochemical rationale for the use of β -lactam- β -lactamase inhibitor combinations. *Antimicrob. Agents Chemother.* **57**, 6085–6096 (2013).

81. Egesborg, P., Carlettini, H., Volpato, J. P. & Doucet, N. Combinatorial active-site variants confer sustained clavulanate resistance in BlaC β -lactamase from *Mycobacterium tuberculosis*. *Protein Sci.* **24**, 534–544 (2015).
82. Alen, I. van *et al.* Mutation G132S enhances resistance of *Mycobacterium tuberculosis* β -lactamase against sulbactam. *Biochemistry* **60**, 2236–2245 (2021).
83. Elings, W. *et al.* Two β -lactamase variants with reduced clavulanic acid inhibition display different millisecond dynamics. *Antimicrob. Agents Chemother.* **65**, (2021).
84. Soroka, D. *et al.* Hydrolysis of clavulanate by *Mycobacterium tuberculosis* β -lactamase BlaC harboring a canonical SDN motif. *Antimicrob. Agents Chemother.* **59**, 5714–5720 (2015).
85. Soroka, D. *et al.* Inhibition of β -lactamases of mycobacteria by avibactam and clavulanate. *J. Antimicrob. Chemother.* **72**, 1081–1088 (2017).
86. Abraham, E. Roots: Selective reminiscences of β -lactam antibiotics: Early research on penicillin and cephalosporins. *Bioessays* **12**, 601–606 (1990).
87. Davies, J. Origins and evolution of antibiotic resistance. *Microbiologia* **12**, 9–16 (1996).
88. Nielsen, J. B. & Lampen, J. O. Membrane-bound penicillinases in Gram-positive bacteria. *J. Biol. Chem.* **257**, 4490–4495 (1982).
89. Ambler, R. P. *et al.* A standard numbering scheme for the Class A β -lactamases. *Biochem. J.* **276**, 269–270 (1991).
90. Knott-Hunziker, V. *et al.* Active sites of beta-lactamases. The chromosomal beta-lactamases of *Pseudomonas aeruginosa* and *Escherichia coli*. *Biochem. J.* **201**, 621–7 (1982).
91. Pernot, L. *et al.* Crystal structures of the class D β -lactamase OXA-13 in the native form and in complex with meropenem. *J. Mol. Biol.* **310**, 859–874 (2001).
92. Sielecki, A. *et al.* Molecular structure of the acyl-enzyme intermediate in β -lactam hydrolysis at 1.7 Å resolution. *Nature* **359**, 700–705 (2003).
93. Carfi, A. *et al.* The 3-D structure of a zinc metallo-beta-lactamase from *Bacillus cereus* reveals a new type of protein fold. *EMBO J.* **14**, 4914–21 (1995).
94. Wang, Z., Fast, W. & Benkovic, S. J. On the mechanism of the metallo- β -lactamase from *Bacteroides fragilis*. *Biochemistry* **38**, 10013–10023 (1999).
95. Macheboeuf, P., Contreras-Martel, C., Job, V., Dideberg, O. & Dessen, A. Penicillin binding proteins: key players in bacterial cell cycle and drug resistance processes. *FEMS Microbiol. Rev.* **30**, 673–691 (2006).
96. Sauvage, E., Kerff, F., Terrak, M., Ayala, J. A. & Charlier, P. The penicillin-binding proteins: structure and role in peptidoglycan biosynthesis. *FEMS Microbiol. Rev.* **32**, 234–258 (2008).
97. Massova, I. & Mobashery, S. Kinship and diversification of bacterial penicillin-binding proteins and β -lactamases. *Antimicrob. Agents Chemother.* **42**, 1–17 (1998).
98. Bush, K. Characterization of β -lactamases. *Antimicrob. Agents Chemother.* **33**, 259–263 (1989).
99. Bush, K., Jacoby, G. A. & Medeiros, A. A. A functional classification scheme for β -lactamases and its correlation with molecular structure. *Antimicrob. Agents Chemother.* **39**, 1211–1233 (1995).
100. Bush, K. & Jacoby, G. A. Updated functional classification of β -lactamases. *Antimicrob. Agents Chemother.* **54**, 969–976 (2010).
101. Wang, F., Cassidy, C. & Sacchettini, J. C. Crystal structure and activity studies of the *Mycobacterium tuberculosis* β -lactamase reveal its critical role in resistance to β -lactam antibiotics. *Antimicrob. Agents Chemother.* **50**, 2762–2771 (2006).
102. Hugonnet, J. E. & Blanchard, J. S. Irreversible inhibition of the *Mycobacterium tuberculosis* β -lactamase by clavulanate. *Biochemistry* **46**, 11998–12004 (2007).
103. Tremblay, L. W., Fan, F. & Blanchard, J. S. Biochemical and structural characterization of *Mycobacterium tuberculosis* beta-lactamase with the carbapenems ertapenem and doripenem. *Biochemistry* **49**, 3766–3773 (2010).
104. Leiros, H.-K. S. *et al.* His224 alters the R2 drug binding site and Phe218 influences the catalytic efficiency of the metallo- β -lactamase VIM-7. *Antimicrob. Agents Chemother.* **58**, 4826–4836 (2014).
105. Na, J.-H., An, Y. J. & Cha, S.-S. GMP and IMP are competitive inhibitors of CMY-10, an extended-spectrum class C β -lactamase. *Antimicrob. Agents Chemother.* **61**, e00098-17 (2017).
106. Golemi, D., Maveyraud, L., Vakulenko, S., Samama, J. P. & Mobashery, S. Critical involvement of a carbamylated lysine in catalytic function of class D beta-lactamases. *Proc. Natl. Acad. Sci. U. S. A.* **98**, 14280–14285 (2001).
107. Yamada, M. *et al.* Crystal structure of cefditoren complexed with *Streptococcus pneumoniae* penicillin-binding protein 2X: structural basis for its high antimicrobial activity. *Antimicrob. Agents Chemother.* **51**, 3902–3907 (2007).
108. Armon, A., Graur, D. & Ben-Tal, N. ConSurf: An algorithmic tool for the identification of functional regions in proteins by surface mapping of phylogenetic information. *J. Mol. Biol.* **307**, 447–463 (2001).
109. Ashkenazy, H., Erez, E., Martz, E., Pupko, T. & Ben-Tal, N. ConSurf 2010: Calculating evolutionary conservation in sequence and structure of proteins and nucleic acids. *Nucleic Acids Res.* **38**, 529–533 (2010).
110. Strynadka, N. C. J. *et al.* Molecular structure of the acyl-enzyme intermediate in β -lactam hydrolysis at 1.7 Å resolution. *Nature* **359**, 700–705 (1992).
111. Díaz, N., Sordo, T. L., Merz, K. M. J. & Suárez, D. Insights into the acylation mechanism of class A beta-lactamases from molecular dynamics simulations of the TEM-1 enzyme complexed with benzylpenicillin. *J. Am. Chem. Soc.* **125**, 672–684 (2003).
112. Knox, J. R., Moews, P. C., Escobar, W. A. & Fink, A. L. A catalytically-impaired class A beta-lactamase: 2 Å crystal structure and kinetics of the *Bacillus licheniformis* E166A mutant. *Protein Eng.* **6**, 11–18 (1993).
113. Guillaume, G. *et al.* Site-directed mutagenesis of glutamate 166 in two beta-lactamases. Kinetic and molecular modeling studies. *J. Biol. Chem.* **272**, 5438–5444 (1997).
114. Meroueh, S. O., Fisher, J. E., Schlegel, H. B. & Mobashery, S. Ab initio QM/MM study of class A beta-lactamase acylation: dual participation of Glu166 and Lys73 in a concerted base promotion of Ser70. *J. Am. Chem. Soc.* **127**, 15397–15407 (2005).
115. Herzberg, O. & Moulton, J. Bacterial resistance to beta-lactam antibiotics: crystal structure of beta-lactamase from *Staphylococcus aureus* PC1 at 2.5 Å resolution. *Science* **236**, 694–701 (1987).
116. Herzberg, O. Refined crystal structure of β -lactamase from *Staphylococcus aureus* PC1 at 2.0 Å resolution. *J. Mol. Biol.* **217**, 701–719 (1991).

117. Bennur, T., Kumar, A. R., Zinjarde, S. & Javdekar, V. Nocardiosis species: Incidence, ecological roles and adaptations. *Microbiol. Res.* **174**, 33–47 (2015).
118. Ellerby, L. M., Escobar, W. A., Fink, A. L., Mitchinson, C. & Wells, J. A. The role of lysine-234 in beta-lactamase catalysis probed by site-directed mutagenesis. *Biochemistry* **29**, 5797–5806 (1990).
119. Lenfant, F., Labia, R. & Masson, J. M. Replacement of lysine 234 affects transition state stabilization in the active site of beta-lactamase TEM1. *J. Biol. Chem.* **169**, 17187–17194 (1991).
120. Lim, D. *et al.* Insights into the molecular basis for the carbenicillinase activity of PSE-4 β -lactamase from crystallographic and kinetic studies. *Biochemistry* **40**, 395–402 (2001).
121. Mendonça, N. *et al.* The Lys234Arg substitution in the enzyme SHV-72 is a determinant for resistance to clavulanic acid inhibition. *Antimicrob. Agents Chemother.* **52**, 1806–1811 (2008).
122. Soeung, V. *et al.* A drug-resistant β -lactamase variant changes the conformation of its active site proton shuttle to alter substrate specificity and inhibitor potency. *J. Biol. Chem.* 18239–18255 (2020).
123. Patel, M. P. *et al.* Synergistic effects of functionally distinct substitutions in β -lactamase variants shed light on the evolution of bacterial drug resistance. *J. Biol. Chem.* **293**, 17971–17984 (2018).
124. Banerjee, S. *et al.* Probing the non-proline cis peptide bond in β -lactamase from *Staphylococcus aureus* PC1 by the replacement Asn136 \rightarrow Ala. *Biochemistry* **36**, 10857–10866 (1997).
125. Jacob, F., Joris, B., Lepage, S., Dusart, J. & Frère, J. M. Role of the conserved amino acids of the ‘SDN’ loop (Ser130, Asp131 and Asn132) in a class A beta-lactamase studied by site-directed mutagenesis. *Biochem. J.* **271**, 399–406 (1990).
126. Swarén, P. *et al.* Electrostatic analysis of TEM1 β -lactamase: effect of substrate binding, steep potential gradients and consequences of site-directed mutations. *Structure* **3**, 603–613 (1995).
127. Wang, X., Minasov, G. & Shoichet, B. K. Evolution of an antibiotic resistance enzyme constrained by stability and activity trade-offs. *J. Mol. Biol.* **320**, 85–95 (2002).
128. Vakulenko, S. B., Tóth, M., Taibi, P., Mobashery, S. & Lerner, S. A. Effects of Asp-179 mutations in TEMpUC19 beta-lactamase on susceptibility to beta-lactams. *Antimicrob. Agents Chemother.* **39**, 1878–1880 (1995).
129. Vakulenko, S. B. *et al.* Effects on substrate profile by mutational substitutions at positions 164 and 179 of the class A TEM(pUC19) beta-lactamase from *Escherichia coli*. *J. Biol. Chem.* **274**, 23052–23060 (1999).
130. Castanheira, M. *et al.* Analyses of a ceftazidime-avibactam-resistant *Citrobacter freundii* isolate carrying bla (KPC-2) reveals a heterogeneous population and reversible genotype. *mSphere* **3**, (2018).
131. Avci, F. G., Altinisik, F. E., Vardar Ulu, D., Ozkirimli Olmez, E. & Sariyar Akbulut, B. An evolutionarily conserved allosteric site modulates beta-lactamase activity. *J. Enzyme Inhib. Med. Chem.* **31**, 33–40 (2016).
132. Meneksedag, D., Dogan, A., Kanlikilicer, P. & Ozkirimli, E. Communication between the active site and the allosteric site in class A beta-lactamases. *Comput. Biol. Chem.* **43**, 1–10 (2013).
133. Sitbon, E. & Pietrovski, S. Occurrence of protein structure elements in conserved sequence regions. *BMC Struct. Biol.* **7**, 1–15 (2007).
134. Saldaño, T. E., Monzon, A. M., Parisi, G. & Fernandez-Alberti, S. Evolutionary conserved positions define protein conformational diversity. *PLoS Comput. Biol.* **12**, 1–25 (2016).
135. Medeiros, A. A. β -Lactamases. *Br. Med. Bull.* **40**, 18–27 (1984).
136. Petrosino, J., Cantu, C. & Palzkill, T. β -Lactamases: Protein evolution in real time. *Trends Microbiol.* **6**, 323–327 (1998).
137. Bonomo, R. A., Rudin, S. D. & Shlaes, D. M. OHIO-1 β -lactamase mutants: Asp179Gly mutation confers resistance to ceftazidime. *FEMS Microbiol. Lett.* **152**, 275–278 (1997).
138. Vakulenko, S. & Golemi, D. Mutant TEM β -lactamase producing resistance to ceftazidime, ampicillins, and β -lactamase inhibitors. *Antimicrob. Agents Chemother.* **46**, 646–653 (2002).
139. Stürenburg, E., Kühn, A., Mack, D. & Laufs, R. A novel extended-spectrum beta-lactamase CTX-M-23 with a P167T substitution in the active-site omega loop associated with ceftazidime resistance. *J. Antimicrob. Chemother.* **54**, 406–409 (2004).
140. Berezin, C. *et al.* ConSeq: The identification of functionally and structurally important residues in protein sequences. *Bioinformatics* **20**, 1322–1324 (2004).
141. Tassoni, R., Blok, A., Pannu, N. S. & Ubbink, M. New conformations of acylation adducts of inhibitors of β -lactamase from *Mycobacterium tuberculosis*. *Biochemistry* **58**, 997–1009 (2019).
142. Lamotte-Brasseur, J. *et al.* Mechanism of acyl transfer by the class A serine β -lactamase of *Streptomyces albus* G. *Biochem. J.* **279**, 213–221 (1991).
143. Tremblay, L. W., Hugonnet, J. & Blanchard, J. S. Structure of the covalent adduct formed between *Mycobacterium tuberculosis*. *Am. Chem. Soc.* **47**, 5312–5316 (2008).
144. Juteau, J. M., Billings, E., Knox, J. R. & Levesque, R. C. Site-saturation mutagenesis and three-dimensional modelling of ROB-1 define a substrate binding role of Ser130 in class A beta-lactamases. *Protein Eng.* **5**, 693–701 (1992).
145. Chikunova, A. *et al.* Conserved residues Glu37 and Trp229 play an essential role in protein folding of β -lactamase. *FEBS J.* **288**, 5708–5722 (2021).
146. Delmas, J., Robin, F., Bittar, F., Chanal, C. & Bonnet, R. Unexpected enzyme TEM-126: Role of mutation Asp179Glu. *Antimicrob. Agents Chemother.* **49**, 4280–4287 (2005).
147. McDonough, J. A. *et al.* Identification of functional Tat signal sequences in *Mycobacterium tuberculosis* proteins. *J. Bacteriol.* **190**, 6428–6438 (2008).
148. Gronenborn, A. M. & Clore, G. M. Rapid screening for structural integrity of expressed proteins by heteronuclear NMR spectroscopy. *Protein Sci.* **5**, 174–177 (1996).
149. Lobkovsky, A. E., Wolf, Y. I. & Koonin, E. V. Universal distribution of protein evolution rates as a consequence of protein folding physics. *Proc. Natl. Acad. Sci. U. S. A.* **107**, 2983–2988 (2010).
150. Philip, A. F., Kumauchi, M. & Hoff, W. D. Robustness and evolvability in the functional anatomy of a PER-ARNT-SIM (PAS) domain. *Proc. Natl. Acad. Sci. U. S. A.* **107**, 17986–17991 (2010).
151. Zayner, J. P., Antoniou, C., French, A. R., Hause, R. J. & Sosnick, T. R. Investigating models of protein function and allostery with a widespread mutational analysis of a light-activated protein. *Biophys. J.* **105**, 1027–1036 (2013).
152. Allocati, N., Masulli, M., Pietracupa, M., Federici, L. & Di Ilio, C. Evolutionary conserved structural motifs in bacterial GST (glutathione S-transferase) are involved in protein folding and stability. *Biochem. J.* **394**, 11–17 (2006).

153. Yampolsky, L. Y. & Stoltzfus, A. The exchangeability of amino acids in proteins. *Genetics* **170**, 1459–1472 (2005).
154. Marsh, L. A model for protein sequence evolution based on selective pressure for protein stability: Application to hemoglobins. *Evol. Bioinforma.* **2009**, 107–118 (2009).
155. Tokuriki, N. & Tawfik, D. S. Chaperonin overexpression promotes genetic variation and enzyme evolution. *Nature* **459**, 668–673 (2009).
156. Karshikoff, A., Nilsson, L. & Ladenstein, R. Rigidity versus flexibility: the dilemma of understanding protein thermal stability. *FEBS J.* **282**, 3899–3917 (2015).
157. Andrews, L. D., Fenn, T. D. & Herschlag, D. Ground state destabilization by anionic nucleophiles contributes to the activity of phosphoryl transfer enzymes. *PLoS Biol.* **11**, e1001599 (2013).
158. Modi, T., Campitelli, P., Kazan, I. C. & Ozkan, S. B. Protein folding stability and binding interactions through the lens of evolution: a dynamical perspective. *Curr. Opin. Struct. Biol.* **66**, 207–215 (2021).
159. Veronica R. Moorman, Kathleen G. Valentine, Sabrina Bédard, Vignesh Kasinath, Jakob Dogan, Fiona M. Love, and A. J. W. Dynamic and thermodynamic response of the Ras protein Cdc42Hs upon association with the effector domain of PAK3. *J Mol Biol.* **426**, 3520–3538 (2015).
160. Pabis, A., Risso, V. A., Sanchez-Ruiz, J. M. & Kamerlin, S. C. Cooperativity and flexibility in enzyme evolution. *Curr. Opin. Struct. Biol.* **48**, 83–92 (2018).
161. Whitacre, J. M. Degeneracy: A link between evolvability, robustness and complexity in biological systems. *Theor. Biol. Med. Model.* **7**, 1–12 (2010).
162. Payne, J. *et al.* Transition bias influences the evolution of antibiotic resistance in *Mycobacterium tuberculosis*. *PLoS Biol.* **17**, (2018).
163. Consortium, T. U. UniProt: the universal protein knowledgebase in 2021. *Nucleic Acids Res.* **49**, 480–489 (2021).
164. Katoh, K., Misawa, K., Kuma, K. I. & Miyata, T. MAFFT: A novel method for rapid multiple sequence alignment based on fast Fourier transform. *Nucleic Acids Res.* **30**, 3059–3066 (2002).
165. McDonough, J. A., Hacker, K. E., Flores, A. R., Pavelka, M. S. & Braunstein, M. The twin-arginine translocation pathway of *Mycobacterium smegmatis* is functional and required for the export of mycobacterial β -lactamases. *J. Bacteriol.* **187**, 7667–7679 (2005).
166. Raran-Kurussi, S., Cherry, S., Zhang, D. & Waugh, D. S. Removal of affinity tags with TEV protease. *Methods Mol Biol.* **1586**, 221–230 (2017).
167. Skinner, S. P. *et al.* CcpNmr AnalysisAssign: a flexible platform for integrated NMR analysis. *J. Biomol. NMR* **66**, 111–124 (2016).
168. Cartwright, S. J., Tan, A. K. & Fink, A. L. Trapping the acyl-enzyme intermediate in β -lactamase I catalysis. *Biochem. J.* **263**, 905–912 (1989).
169. Waley, P. J. M. and S. G. β -Lactamase I from *Bacillus cereus*. *Biochem J* **248**, 657–662 (1987).
170. Roccatano, D. *et al.* Dynamical aspects of TEM-1 β -Lactamase probed by molecular dynamics. *J. Comput. Aided. Mol. Des.* **19**, 329–340 (2005).
171. Ruggiero, M. *et al.* Crystal structure of the extended-spectrum β -lactamase PER-2 and insights into the role of specific residues in the interaction with β -lactams and β -lactamase inhibitors. *Antimicrob. Agents Chemother.* **58**, 5994–6002 (2014).
172. Tranier, S. *et al.* The high resolution crystal structure for class A β -lactamase PER-1 reveals the bases for its increase in breadth of activity. *J. Biol. Chem.* **275**, 28075–28082 (2000).
173. Huang, W., Petrosino, J., Hirsch, M., Shenkin, P. S. & Palzkill, T. Amino acid sequence determinants of β -lactamase structure and activity. *J. Mol. Biol.* **258**, 688–703 (1996).
174. Poirel, L. *et al.* GES-2, a class A β -lactamase from *Pseudomonas aeruginosa* with increased hydrolysis of imipenem. *Antimicrob. Agents Chemother.* **45**, 2598–2603 (2001).
175. Smith, C. A., Caccamo, M., Kantardjieff, K. A. & Vakulenko, S. Structure of GES-1 at atomic resolution: Insights into the evolution of carbapenamase activity in the class A extended-spectrum β -lactamases. *Acta Crystallogr. Sect. D Biol. Crystallogr.* **63**, 982–992 (2007).
176. Klein, R. *et al.* Targeting the class a carbapenamase GES-5 via virtual screening. *Biomolecules* **10**, 1–10 (2020).
177. Bebrone, C. *et al.* GES-18, a new carbapenem-hydrolyzing GES-type β -lactamase from *Pseudomonas aeruginosa* that contains Ile80 and Ser170 residues. *Antimicrob. Agents Chemother.* **57**, 396–401 (2013).
178. Delbrück, H. *et al.* Kinetic and crystallographic studies of extended-spectrum GES-11, GES-12, and GES-14 β -lactamases. *Antimicrob. Agents Chemother.* **56**, 5618–5625 (2012).
179. Rogers, M. B., Parker, A. C. & Smith, C. J. Cloning and characterization of the endogenous cephalosporinase gene, *cepA*, from *Bacteroides fragilis* reveals a new subgroup of Ambler class A β -lactamases. *Antimicrob. Agents Chemother.* **37**, 2391–2400 (1993).
180. Morin, A. S., Poirel, L., Mory, F., Labia, R. & Nordmann, P. Biochemical-genetic analysis and distribution of DES-1, an Ambler class A extended-spectrum β -lactamase from *Desulfovibrio desulfuricans*. *Antimicrob. Agents Chemother.* **46**, 3215–3222 (2002).
181. Sawyer, L. & James, M. N. G. Carboxyl–carboxylate interactions in proteins. *Nature* **295**, 79–80 (1982).
182. Lin, J., Pozharski, E. & Wilson, M. A. Short Carboxylic Acid–Carboxylate Hydrogen Bonds Can Have Fully Localized Protons. *Biochemistry* **56**, 391–402 (2017).
183. Nichols, D. A. *et al.* Ligand-induced proton transfer and low-barrier hydrogen bond revealed by X-ray crystallography. *J. Am. Chem. Soc.* **137**, 8086–8095 (2016).
184. Huynh, K. & Partch, C. L. Analysis of protein stability and ligand interactions by thermal shift assay. *Curr. Protoc. protein Sci.* **79**, 28.9.1–28.9.14 (2015).
185. Jacob-Dubuisson, F., Lamotte-Brasseur, J., Dideberg, O., Joris, B. & Frère, J. M. Arginine 220 is a critical residue for the catalytic mechanism of the *Streptomyces albus* β -lactamase. *Protein Eng. Des. Sel.* **4**, 811–819 (1991).
186. Yang, Y., Rasmussen, B. A. & Shlaes, D. M. Class A β -lactamases - Enzyme-inhibitor interactions and resistance. *Pharmacol. Ther.* **83**, 141–151 (1999).
187. Ruggiero, M. *et al.* Impact of mutations at Arg220 and Thr237 in PER-2 β -Lactamase on conformation, activity, and susceptibility to inhibitors. *Antimicrob. Agents Chemother.* **61**, 1–8 (2017).

188. Atanasov, B. P., Mustafi, D. & Makinen, M. W. Protonation of the β -lactam nitrogen is the trigger event in the catalytic action of class A β -lactamases. *Proc. Natl. Acad. Sci. U. S. A.* **97**, 3160–3165 (2000).
189. Marciano, D. C., Brown, N. G. & Palzkill, T. Analysis of the plasticity of location of the Arg244 positive charge within the active site of the TEM-1 β -lactamase. *Protein Sci.* **18**, 2080–2089 (2009).
190. Michiyosi Nukaga, Christopher R. Bethel, Jodi M. Thomson, Andrea M. Hujer, Anne Distler, Vernon E. Anderson, James R. Knox, and R. A. B. Inhibition of Class A β -Lactamases by Carbapenems: Crystallographic Observation of Two Conformations of Meropenem in SHV-1. *Bone* **23**, 1–7 (2008).
191. Jelsch, C., Mourey, L., Masson, J. M. & Samama, J. P. Crystal structure of Escherichia coli TEM1 β lactamase at 1.8 Å resolution. *Proteins Struct. Funct. Bioinforma.* **16**, 364–383 (1993).
192. Ibuka, A. S. *et al.* Crystal structure of extended-spectrum beta-lactamase Toho-1: insights into the molecular mechanism for catalytic reaction and substrate specificity expansion. *Biochemistry* **42**, 10634–10643 (2003).
193. Sauvage, E. *et al.* Crystal structure of the mycobacterium fortuitum class a β -lactamase: Structural basis for broad substrate specificity. *Antimicrob. Agents Chemother.* **50**, 2516–2521 (2006).
194. Jensen, M. R. Capturing the structure of low-populated aromatic ring flipping intermediate. in *ICMRBS: Emerging Topics in Biomolecular Magnetic Resonance webinar 2021-05-13*
195. Schütz, A. K., Rennella, E. & Kay, L. E. Exploiting conformational plasticity in the AAA+ protein VCP/p97 to modify function. *Proc. Natl. Acad. Sci. U. S. A.* **114**, E6822–E6829 (2017).
196. Zimmerman, M. I. *et al.* Prediction of new stabilizing mutations based on mechanistic insights from Markov State Models. *ACS Cent. Sci.* **3**, 1311–1321 (2017).
197. Neu, H. C. The crisis in antibiotic resistance. *Science (80-.)*. **257**, 1064–1073 (1992).
198. Pastor, N., Piñero, D., Valdés, A. M. & Soberón, X. Molecular evolution of class A β lactamases: phylogeny and patterns of sequence conservation. *Mol. Microbiol.* **4**, 1957–1965 (1990).
199. Lim, H. M. & Pene, J. J. Mutations affecting the catalytic activity of Bacillus cereus 5/B/6 β -lactamase II. *J. Biol. Chem.* **264**, 11682–11687 (1989).
200. Little, C., Emanuel, E. L., Gagnon, J. & Waley, S. G. Identification of an essential glutamic acid residue in β -lactamase II from Bacillus cereus. *Biochem. J.* **233**, 465–469 (1986).
201. Horn, J. R. & Shoichet, B. K. Allosteric inhibition through core disruption. *J. Mol. Biol.* **336**, 1283–1291 (2004).
202. Miller, S., Janin, J., Lesk, A. M. & Chothia, C. Interior and surface of monomeric proteins. *J. Mol. Biol.* **196**, 641–656 (1987).
203. Navarro, S., Villar-Piqué, A. & Ventura, S. Selection against toxic aggregation-prone protein sequences in bacteria. *Biochim. Biophys. Acta - Mol. Cell Res.* **1843**, 866–874 (2014).
204. Pervushin, K., Riek, R., Wider, G. & Wüthrich, K. Attenuated T2 relaxation by mutual cancellation of dipole-dipole coupling and chemical shift anisotropy indicates an avenue to NMR structures of very large biological macromolecules in solution. *Proc. Natl. Acad. Sci. U. S. A.* **94**, 12366–12371 (1997).
205. Lavanya, P., Ramaiah, S. & Anbarasu, A. Cation- π interactions in β -lactamases: the role in structural stability. *Cell Biochemistry and Biophysics* **66**, 147–155 (2013).
206. Fonzé, E. *et al.* Crystal structures of the Bacillus licheniformis BS3 class a β -lactamase and of the acyl-enzyme adduct formed with cefoxitin. *Biochemistry* **41**, 1877–1885 (2002).
207. Smith, C. A., Caccamo, M., Kantardjieff, K. A. & Vakulenko, S. Structure of GES-1 at atomic resolution: Insights into the evolution of carbapenamase activity in the class A extended-spectrum β -lactamases. *Acta Crystallogr. Sect. D Biol. Crystallogr.* **63**, 982–992 (2007).
208. Kudlicki, W., Chirgwin, J., Kramer, G. & Hardesty, B. Folding of an enzyme into an active conformation while bound as peptidyl-tRNA to the ribosome. *Biochemistry* **34**, 14284–14287 (1995).
209. Javed, A., Christodoulou, J., Cabrita, L. D. & Orlova, E. V. The ribosome and its role in protein folding: Looking through a magnifying glass. *Acta Crystallogr. Sect. D Struct. Biol.* **73**, 509–521 (2017).
210. Mcgaughey, G. B., Gagne, M. & Rappe, A. K. π -Stacking interactions. Alive and well in proteins. *Biol. Chem.* **273**, 15458–15463 (1998).
211. Zondlo, N. J. Aromatic-Proline interactions: Electronically tubale CH/ π i interactions. *Acc Chem Res.* **46**, 1039–1049 (2013).
212. Lada Biedermannova, Kevin E. Riley, Karel Berka, P. H. and J. V. Another role of proline: stabilization interactions in proteins and protein complexes concerning proline and tryptophan. *Phys. Chem. Chem. Phys.* **10**, 2581–2583 (2008).
213. St-Jean, M., Izard, T. & Sygusch, J. A hydrophobic pocket in the active site of glycolytic aldolase mediates interactions with Wiskott-Aldrich syndrome protein. *J. Biol. Chem.* **282**, 14309–14315 (2007).
214. Black, K. M., Clark-Lewis, I. & Wallace, C. J. A. Conserved tryptophan in cytochrome c: Importance of the unique side-chain features of the indole moiety. *Biochem. J.* **359**, 715–720 (2001).
215. Ptitsyn, O. B. Molten globule and protein folding. *Adv. Protein Chem.* **47**, 83–229 (1995).
216. Ptitsyn, O. B. & Semisotnov, G. V. Evidence for a molten globule state as a general intermediate in protein folding. **262**, 1–5 (2001).
217. Yon, J. M. Protein folding: A perspective for biology, medicine and biotechnology. *Brazilian J. Med. Biol. Res.* **34**, 419–435 (2001).
218. Shiber, A. & Ravid, T. Chaperoning proteins for destruction: Diverse roles of Hsp70 chaperones and their co-chaperones in targeting misfolded proteins to the proteasome. *Biomolecules* **4**, 704–724 (2014).
219. Esser, C., Alberti, S. & Höhfeld, J. Cooperation of molecular chaperones with the ubiquitin/proteasome system. *Biochim. Biophys. Acta - Mol. Cell Res.* **1695**, 171–188 (2004).
220. Kettern, N., Dreiseidler, M., Tawo, R. & Höhfeld, J. Chaperone-assisted degradation: Multiple paths to destruction. *Biol. Chem.* **391**, 481–489 (2010).
221. Sherman MYu & Goldberg, A. L. Involvement of the chaperonin dnaK in the rapid degradation of a mutant protein in Escherichia coli. *EMBO J.* **11**, 71–77 (1992).
222. Kandror, O., Busconi, L., Sherman, M. & Goldberg, A. L. Rapid degradation of an abnormal protein in Escherichia coli involves the chaperones GroEL and GroES. *J. Biol. Chem.* **269**, 23575–23582 (1994).
223. Artimo, P. *et al.* ExPASy: SIB bioinformatics resource portal. *Nucleic Acids Res.* **40**, 597–603 (2012).
224. Newman, J. *et al.* Towards rationalization of crystallization screening for small- To medium-sized academic laboratories: The PACT/JCSG+ strategy. *Acta Crystallogr. Sect. D Biol. Crystallogr.* **61**, 1426–1431 (2005).

225. Svensson, O., Gilski, M., Nurizzo, D. & Bowler, M. W. Multi-position data collection and dynamic beam sizing: recent improvements to the automatic data-collection algorithms on MASSIF-1. *Acta Crystallogr. Sect. D Struct. Biol.* **74**, 433–440 (2018).
226. Kabsch, W. XDS. *Acta Crystallogr. Sect. D Biol. Crystallogr.* **66**, 125–132 (2010).
227. Evans, P. R. An introduction to data reduction: Space-group determination, scaling and intensity statistics. *Acta Crystallogr. Sect. D Biol. Crystallogr.* **67**, 282–292 (2011).
228. Winn, M. D. *et al.* Overview of the CCP4 suite and current developments. *Acta Crystallogr. Sect. D Biol. Crystallogr.* **67**, 235–242 (2011).
229. Chen, V. B. *et al.* MolProbity: All-atom structure validation for macromolecular crystallography. *Acta Crystallogr. Sect. D Biol. Crystallogr.* **66**, 12–21 (2010).
230. Joosten, R. P., Long, F., Murshudov, G. N. & Perrakis, A. The PDB-REDO server for macromolecular structure model optimization. *IUCrJ* **1**, 213–220 (2014).
231. Sobolev, O. V. *et al.* A global Ramachandran score identifies protein structures with unlikely stereochemistry. *Structure* **28**, 1249–1258.e2 (2020).
232. Vakulenko, S. B. *et al.* Effects on substrate profile by mutational substitutions at positions 164 and 179 of the class A TEM(pUC19) β -lactamase from *Escherichia coli*. *J. Biol. Chem.* **274**, 23052–23060 (1999).
233. Casthanheira, M. *et al.* Analyses of a ceftazidime-avibactam-resistant *Citrobacter* population and reversible genotype. *Mosphere* **3**, 1–8 (2018).
234. Thomas, V. L. *et al.* Structural consequences of the inhibitor-resistant Ser130Gly substitution in TEM beta-lactamase. *Biochemistry* **44**, 9330–9338 (2005).
235. Levitt, P. S. *et al.* Exploring the role of a conserved class A residue in the Ω -loop of KPC-2 β -lactamase: A mechanism for ceftazidime hydrolysis. *J. Biol. Chem.* **287**, 31783–31793 (2012).
236. Nitanaï, Y. *et al.* The catalytic efficiency (kcat/Km) of the class A β -lactamase Toho-1 correlates with the thermal stability of its catalytic intermediate analog. *Biochim. Biophys. Acta - Proteins Proteomics* **1804**, 684–691 (2010).
237. Majiduddin, F. K. & Palzkill, T. An analysis of why highly similar enzymes evolve differently. *Genetics* **163**, 457–466 (2003).
238. Winkler, M. L., Papp-Wallace, K. M. & Bonomo, R. A. Activity of ceftazidime/avibactam against isogenic strains of *Escherichia coli* containing KPC and SHV β -lactamases with single amino acid substitutions in the Ω -loop. *J. Antimicrob. Chemother.* **70**, 2279–2286 (2015).
239. Patel, M. P. *et al.* The drug-resistant variant P167S expands the substrate profile of CTX-M β -lactamases for oxyimino-cephalosporin antibiotics by enlarging the active site upon acylation. *Biochemistry* **56**, 3443–3453 (2017).
240. Barnes, M. D. *et al.* *Klebsiella pneumoniae* carbapenemase-2 (KPC-2), substitutions at Ambler position Asp179, and resistance to ceftazidime-avibactam: unique antibiotic-resistant phenotypes emerge from β -lactamase protein engineering. *MBio* **8**, (2017).
241. Herzberg, O., Kapadia, G., Blanco, B., Smith, T. S. & Coulson, A. Structural basis for the inactivation of the P54 mutant of β -lactamase from *Staphylococcus aureus* PC1. *Biochemistry* **30**, 9503–9509 (1991).
242. Bush, K. β -Lactamase inhibitors from laboratory to clinic. *Clin. Microbiol. Rev.* **1**, 109–123 (1988).
243. Lee, N., Yuen, K.-Y. & Kumana, C. R. Clinical role of β -lactam/ β -lactamase inhibitor combinations. *Drugs* **63**, 1511–24 (2003).
244. Reading, C. & Cole, M. Clavulanic acid: a β -lactamase-inhibiting β -lactam from *Streptomyces clavuligerus*. *Antimicrob. Agents Chemother.* **11**, 852–857 (1977).
245. English, A. R., Retsema, J. A., Girard, A. E., Lynch, J. E. & Barth, W. E. CP-45,899, a β -lactamase inhibitor that extends the antibacterial spectrum of β -lactams: Initial bacteriological characterization. *Antimicrob. Agents Chemother.* **14**, 414–419 (1978).
246. Scholar, E. Sulbactam. in (eds. Enna, S. J. & Bylund, D. B. B. T. C. P. R.) 1–5 (Elsevier, 2007). doi:<https://doi.org/10.1016/B978-008055232-3.62687-X>
247. Therrien, C. & Levesque, R. C. Molecular basis of antibiotic resistance and β -lactamase inhibition by mechanism-based inactivators: perspectives and future directions. *FEMS Microbiol. Rev.* **251–262** (2000).
248. Elings, W. *et al.* Phosphate promotes the recovery of *Mycobacterium tuberculosis* β -lactamase from clavulanic acid inhibition. *Biochemistry* **56**, 6257–6267 (2017).
249. Wang, F., Cassidy, C. & Sacchettini, J. C. Crystal structure and activity studies of the *Mycobacterium tuberculosis* β -lactamase reveal its critical role in resistance to β -lactam antibiotics. *Antimicrob. Agents Chemother.* **50**, 2762–2771 (2006).
250. van Beusekom, L. M. J. Improving protein structure with homology-based information and prior knowledge. (Utrecht University, 2019).
251. Winkler, M. L. *et al.* Design and exploration of novel boronic acid inhibitors reveals important interactions with a clavulanic acid-resistant sulfhydryl-variable (SHV) β -lactamase. *J. Med. Chem.* **56**, 1084–1097 (2013).
252. Zou, T., Risso, V. A., Gavira, J. A., Sanchez-Ruiz, J. M. & Ozkan, S. B. Evolution of conformational dynamics determines the conversion of a promiscuous generalist into a specialist enzyme. *Mol. Biol. Evol.* **32**, 132–143 (2015).
253. Firnberg, E., Labonte, J. W., Gray, J. J. & Ostermeier, M. A comprehensive, high-resolution map of a Gene's fitness landscape. *Mol. Biol. Evol.* **31**, 1581–1592 (2014).
254. Steinberg, B. & Ostermeier, M. Shifting fitness and epistatic landscapes reflect trade-offs along an evolutionary pathway. *J. Mol. Biol.* **428**, 2730–2743 (2016).
255. Otting, G. Protein NMR using paramagnetic ions. *Annu. Rev. Biophys.* **39**, 387–405 (2010).
256. Keizers, P. H. J. & Ubbink, M. Paramagnetic tagging for protein structure and dynamics analysis. *Prog. Nucl. Magn. Reson. Spectrosc.* **58**, 88–96 (2011).
257. Clore, G. M. & Iwahara, J. Theory, practice, and applications of paramagnetic relaxation enhancement for the characterization of transient low-population states of biological macromolecules and their complexes. *Chem. Rev.* **109**, 4108–4139 (2009).
258. Commandeur, S. *et al.* Zebrafish embryo model for assessment of drug efficacy on *Mycobacterium* persisters. *Antimicrob. Agents Chemother.* **64**, (2020).
259. Habjan, E. *et al.* Anti-tuberculosis compound screen using a zebrafish infection model identifies an aspartyl-tRNA synthetase inhibitor. *Dis. Model. Mech.* (2021). doi:10.1242/dmm.049145

260. Cheng, T., Kam, J. Y., Johansen, M. D. & Oehlers, S. H. High content analysis of granuloma histology and neutrophilic inflammation in adult zebrafish infected with *Mycobacterium marinum*. *Micron* **129**, 102782 (2020).
261. Moreira, J. D. *et al.* Functional inhibition of host histone deacetylases (HDACs) enhances in vitro and in vivo anti-mycobacterial activity in human macrophages and in zebrafish. *Front. Immunol.* **11**, 36 (2020).
262. Changeux, J.-P. Allostery and the Monod-Wyman-Changeux model after 50 years. *Annu. Rev. Biophys.* **41**, 103–133 (2012).
263. Petrović, D., Risso, V. A., Kamerlin, S. C. L. & Sanchez-Ruiz, J. M. Conformational dynamics and enzyme evolution. *J. R. Soc. Interface* **15**, (2018).
264. Elings, W. *et al.* β -Lactamase of *mycobacterium tuberculosis* shows dynamics in the active site that increase upon inhibitor binding. *Antimicrob. Agents Chemother.* **64**, (2020).